AZN240726C71000
- 5.94
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca Posts Higher H1 Attributable Profit, Revenue
Express News | FDA Advisory Committee Reviewed Imfinzi For Resectable Non-Small Cell Lung Cancer Based On Phase III Trial Results; AstraZeneca Reports Imfinzi Met Primary Endpoint Of Event-Free Survival And Was Generally Well Tolerated With No New Safety Signals
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Top Midday Stories: US Advance Q2 GDP Rises; Initial Jobless Claims Drop; Ford Earnings Fall; TotalEnergies' Lower Results; AbbVie Raises Guidance; IBM, ServiceNow Report Higher Results
Why AstraZeneca Stock Is Sliding Today
European Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday Trading
U.S. Inflation Reduction Act Is Manageable Headwind in the Near Term, AstraZeneca Executives Say -- Market Talk
Jefferies Remains a Hold on AstraZeneca (AZN)
NHS Rules Risk Depriving Britain of New Medicine, Warns AstraZeneca Boss
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
Sector Update: Health Care Stocks Mixed Premarket Thursday
6-K: Report of foreign private issuer (related to financial reporting)
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
Sector Update: Health Care
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
AstraZeneca Shares Fall Despite Guidance Raise as Drugmaker Warns on Income
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), AstraZeneca (AZN) and Icon (ICLR)